Patents by Inventor Rachael Jane Ritchie

Rachael Jane Ritchie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7998484
    Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: August 16, 2011
    Assignees: Novartis AG, Ottawa Health Research Institute
    Inventors: Steven Griffiths, Rachael Jane Ritchie, Joel Heppell
  • Patent number: 7803924
    Abstract: The hsp60 gene from a strain of Arthrobacter has been isolated and sequenced. The encoded protein is believed to be highly immunogenic, especially in fish, and also has utility as a non-specific adjuvant, and as an adjuvanting carrier for heterologous antigens.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 28, 2010
    Assignee: Novartis AG
    Inventors: Steven Gareth Griffiths, Rachael Jane Ritchie, Nathalie C. Simard
  • Publication number: 20100136038
    Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.
    Type: Application
    Filed: November 24, 2009
    Publication date: June 3, 2010
    Inventors: Steven Griffiths, Rachael Jane Ritchie, Joel Heppell
  • Patent number: 7674892
    Abstract: The hsp70 gene from an Arthrobacter species has been isolated and sequenced. The encoded protein is believed to be highly immunogenic, especially in fish, and also has utility as a non-specific adjuvant, and as an adjuvanting carrier for heterologous antigens.
    Type: Grant
    Filed: July 14, 2003
    Date of Patent: March 9, 2010
    Assignee: Novartis AG
    Inventors: Steven Gareth Griffiths, Rachael Jane Ritchie, Nathalie C. Simard
  • Publication number: 20080287664
    Abstract: The hsp60 gene from a strain of Arthrobacter has been isolated and sequenced. The encoded protein is believed to be highly immunogenic, especially in fish, and also has utility as a non-specific adjuvant, and as an adjuvanting carrier for heterologous antigens.
    Type: Application
    Filed: October 26, 2007
    Publication date: November 20, 2008
    Inventors: Steven Gareth Griffiths, Rachael Jane Ritchie, Nathalie C. Simard
  • Patent number: 7128917
    Abstract: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: October 31, 2006
    Assignees: Novartis, AG, Ottawa Health Research Institute
    Inventors: Steven Griffiths, Rachael Jane Ritchie, Joel Heppell